Metastases to Bone

作者: Robert G. Parker , Nora A. Janjan , Michael T. Selch

DOI: 10.1007/978-3-662-05225-9_3

关键词:

摘要: Over 100,000 patients per year in the United States have newly recognized metastases to bone [1]. Usually primary tumor has been identified, but occasionally a metastasis will be first clinical indication of cancer. These lesions may major source pain, neurologic deficit, and hypercalcemia compromise skeletal integrity with potentially disastrous results weight-bearing bone. The most frequent sources are cancers breast, prostate, lung [2, 3]. Metastases from other sites, including kidney, thyroid, endometrium, cervix, bladder, gastrointestinal tract account for less than 20% known [4]. Although ultimate prognosis is poor, many patients, particularly those survive months or even years. Consequently, nearly all need treatment relieve symptoms signs caused by cancer remainder their lives.

参考文章(74)
Robinson Rg, Baxter Kg, Dusing Rw, Spicer Ja, Preston Df, Clinical experience with strontium-89 in prostatic and breast cancer patients. Seminars in Oncology. ,vol. 20, pp. 44- 48 ,(1993)
N A Christakis, E B Lamont, Some Elements of Prognosis in Terminal Cancer Oncology. ,vol. 13, pp. 1165- 1170 ,(1999)
Frank V. Fossella, Leela P. Kasi, Daniel J. Macey, John E. Bayouth, Dosimetry and toxicity of samarium-153-EDTMP administered for bone pain due to skeletal metastases The Journal of Nuclear Medicine. ,vol. 35, pp. 63- 69 ,(1994)
JOHN A. MURRAY, MARK C. BRUELS, ROBERT D. LINDBERG, Irradiation of polymethylmethacrylate. In vitro gamma radiation effect. Journal of Bone and Joint Surgery, American Volume. ,vol. 56, pp. 311- 312 ,(1974) , 10.2106/00004623-197456020-00009
ED Thomas, CD Buckner, M Banaji, RA Clift, A Fefer, N Flournoy, BW Goodell, RO Hickman, KG Lerner, PE Neiman, GE Sale, JE Sanders, J Singer, M Stevens, R Storb, PL Weiden, One hundred patients with acute leukemia treated by chemotherapy, total body irradiation, and allogeneic marrow transplantation. Blood. ,vol. 49, pp. 511- 533 ,(1977) , 10.1182/BLOOD.V49.4.511.511
Duncan M. Ackery, Alexander J. McEwan, Maureen A. Zivanovic, Glen M. Blake, David R. Fine, Richard M. Blaquiere, Strontium-89 therapy: measurement of absorbed dose to skeletal metastases. The Journal of Nuclear Medicine. ,vol. 29, pp. 549- 557 ,(1988)
B A Berrettoni, J R Carter, Mechanisms of cancer metastasis to bone. Journal of Bone and Joint Surgery, American Volume. ,vol. 68, pp. 308- 312 ,(1986) , 10.2106/00004623-198668020-00021
Francis, A.J. Tofe, W.J. Harvey, Correlation of neoplasms with incidence and localization of skeletal metastases: An analysis of 1,355 diphosphonate bone scans. The Journal of Nuclear Medicine. ,vol. 16, pp. 986- 989 ,(1975)
P F Conte, J Latreille, L Mauriac, F Calabresi, R Santos, D Campos, J Bonneterre, G Francini, J M Ford, Delay in progression of bone metastases in breast cancer patients treated with intravenous pamidronate: results from a multinational randomized controlled trial. The Aredia Multinational Cooperative Group. Journal of Clinical Oncology. ,vol. 14, pp. 2552- 2559 ,(1996) , 10.1200/JCO.1996.14.9.2552
A N Serafini, S J Houston, I Resche, D P Quick, F M Grund, P J Ell, A Bertrand, F R Ahmann, E Orihuela, R H Reid, R A Lerski, B D Collier, J H McKillop, G L Purnell, A P Pecking, F D Thomas, K A Harrison, Palliation of pain associated with metastatic bone cancer using samarium-153 lexidronam: a double-blind placebo-controlled clinical trial. Journal of Clinical Oncology. ,vol. 16, pp. 1574- 1581 ,(1998) , 10.1200/JCO.1998.16.4.1574